| This week's sponsor is Premier Research. | | | A Brand New Day for Rare Cancer Study
As cancer's molecular origins emerge and researchers join forces, it's a new day for study of rare oncology. Read our white paper for patient viewpoints and trends in trial design, regulation, and legislation. Premier Research. It's what we do. Best. |
Top Stories Monday, December 12, 2016 In one of the biggest Series A funding rounds ever recorded for a biotech, Germany’s Bayer and Versant Ventures have stumped up $225 million for the launch of BlueRock Therapeutics. Monday, December 12, 2016 Neil Woodford, who has seen his light dim in 2016 as a “star fund manager”, signalled in a brief update with the The Times newspaper that he was to stop investing in the moribund biotech NW Bio after seeing his original investment decimated. Monday, December 12, 2016 Just a week after the former CEO of Alphabet’s venture arm GV was said to be plotting a $230 million life sciences and healthcare fund, Bill Maris has confirmed to news site Recode that he will now be dropping his plans. Monday, December 12, 2016 Seattle Genetics could move beyond its core focus in blood cancers and into the solid tumor setting, if positive early-stage data is backed up by further trials. Monday, December 12, 2016 Swedish biotech BioInvent's worst fears have been realized after it was forced to terminate a trial of its lead drug—multiple myeloma therapy BI-505. Monday, December 12, 2016 Over the past decade, scientists have learned an important lesson about fat cells: Their color plays a vital role in metabolic health. Too much white fat causes obesity and other complications, like diabetes and heart disease. Brown fat burns energy and protects against obesity. Scientists at the University of Pennsylvania may have found a pathway for turning white fat brown. Monday, December 12, 2016 Philips is selling a majority stake of its lighting business, Lumileds, to Apollo Global Management for $2 billion, including debt. The deal comes nearly a year after the company’s bid to offload Lumileds to a Chinese firm fell through due to pressure from U.S. regulators. Monday, December 12, 2016 Alexion still hasn’t wrapped up its internal investigation of a former employee’s sales fraud allegations. But in the meantime, its CEO and CFO are hitting the road. | | | Ipsen's EVP and CSO Claude Bertrand is out the door to join another company, as SVP of global drug devleopment Alexandre Lebeaut leads the R&D division in the interim. Release Accelerator Corporation said it has injected $7 million into a Series A round for cancer resistance therapy biotech ApoGen Biotechnologies. Statement | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA DeviceTalks December 12, 2016 | Newport Beach, CA Drug Development Boot CampTM 2017 November 15-16, 2017 | Boston, MA CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA | 